Scientists split Alzheimer's into two distinct disease paths using blood biomarkers

Researchers have identified early- and late-onset subtypes of Alzheimer's disease using validated biological markers, offering a potential roadmap for more targeted treatment development. The finding could reshape how drugmakers design clinical trials and how clinicians identify patients most likely to benefit from emerging therapies.

Originaltitel: A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer's disease